



# BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presentation and Webcast

**Bergen, Norway, 06 February 2018** – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib (BGB324), a first-in-class selective small molecule AXL inhibitor, as a potential cornerstone therapy for multiple cancer indications, will announce its results for the fourth quarter and full year 2017 on Tuesday, 13 February 2018.

A presentation by BerGenBio's senior management team will take place at 10.00 am CET at:

Felix Konferansesenter, Bryggetorget 3, 0125 Oslo

The presentation will webcast live and the link will be available at [www.bergenbio.com](http://www.bergenbio.com) in the section Investors/Reports and presentations/Webcasts. A recording will be available shortly after the webcast has finished.

The results report and the presentation will be available at [www.bergenbio.com](http://www.bergenbio.com) in the section: Investors/Reports and presentations from 7:00 am CET the same day.

-Ends-

## Contacts

Richard Godfrey

CEO, BerGenBio ASA

[media@bergenbio.com](mailto:media@bergenbio.com)

+47 917 86 304

Tom Henrik Sundby

Finance Director, BerGenBio ASA

[tom.sundby@bergenbio.com](mailto:tom.sundby@bergenbio.com)

+47 477 54 415

David Dible, Mark Swallow, Marine Perrier

Citigate Dewe Rogerson

[bergenbio@citigatedr.co.uk](mailto:bergenbio@citigatedr.co.uk)

+44 207 638 9571

## Forward looking statements

*This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements*

*This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.*